VGI Health Technology Limited

Equities

VTL

AU0000152597

Biotechnology & Medical Research

End-of-day quote National Stock Exchange of Australia Other stock markets 06:00:00 2023-06-28 pm EDT			5-day change	1st Jan Change
0.02 ^AUD	-33.33%		-.--%	-.--%

Feb. 08	VGI Health Technology Limited Reports Earnings Results for the Half Year Ended December 31, 2023	CI
2023	VGI Health Technology Limited Reports Earnings Results for the Full Year Ended June 30, 2023	CI

VGI Health Technology : VTL announces results of 2021 Annual General Meeting

November 16, 2021 at 08:07 pm EST

VGI Health Technology Limited

ABN: 35 111 082 485

Address: Level 45, MLC Centre, 19 Martin Place, Sydney NSW 2000

www.vgiht.com | Tel: +61 2 8279 8908

Results of 2021 Annual General Meeting

Sydney New South Wales, 17 November 2021 - In accordance with section 251AA of the Corporations Act 2001 (Cth), the directors of VGI Health Technology Limited (the Company or NSX:VTL) advise that the shareholders of the Company passed the resolution in the Notice of Meeting dated 22 September 2021.

The resolution was carried out by way of a poll. Details of the resolution and the proxies received in respect of the resolution are set out in the attached summary.

This announcement was authorized for release by the Board of VGI Health Technology Limited.

For more information please contact:

Glenn Tong, CEO and Managing	Catriona Glover, Company
Director	Secretary
Ph: +61 (0) 412 193 350	Tel: +61 (0) 402 328 200
Andrew Crook, Investor and
Media Relations
Ph:+61 (0) 419 788 431

About VGI Health Technology Limited

VGI Health Technology Limited trading as VGI Health Technology is an Australian public listed biotechnology company (NSX:VTL) developing and commercialising novel dietary supplements and prescription medicines based on natural products (tocotrienols) which have wide therapeutic potential, including: Delayed Onset Muscle Soreness, muscle recovery, exercise endurance, Non-Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic SteatoHepatitis (NASH), pancreatic cancer, hyperlipidaemia, hypertension and diabetes. VTL owns and controls patent and other intellectual property rights for novel approaches to non-invasively delivering tocotrienols directly to the target tissues. The Company has a product development program for evidence-based nutraceuticals and a clinical development program for prescription medicines.

For more information see: https://www.vgiht.com

Investors interested in trading shares on the NSX should contact a broker who is an NSX Participant: https://www.nsx.com.au/broker_list_print.asp

Results of 2021 Annual General Meeting

Resolution	Instructions given to validly appointed proxies (as at	Number of votes cast on the poll (where	Resolution
Details	proxy close)				applicable)			Result
Resolution	For	Against	Discretion	Abstain	For	Against	Abstain	Carried/not
								carried
1. Adoption of	10,784,475	534,565	32,659	486	10,817,134	534,565	486	Carried
Remuneration
Report

Attachments

Original Link
Original Document
Permalink

Disclaimer

VGI Health Technology Ltd. published this content on 17 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 November 2021 01:06:07 UTC.

Latest news about VGI Health Technology Limited

VGI Health Technology Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 08	CI
VGI Health Technology Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-06	CI
Certain Ordinary Shares of VGI Health Technology Limited are subject to a Lock-Up Agreement Ending on 28-MAY-2023.	23-05-27	CI
VGI Health Technology Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-15	CI
VGI Health Technology Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-09	CI
VGI Health Technology Limited Auditor Raises 'Going Concern' Doubt	22-08-09	CI
Certain Ordinary Shares of VGI Health Technology Limited are subject to a Lock-Up Agreement Ending on 28-MAY-2022.	22-05-27	CI
ENDRA Life Sciences Expands Pharmaceutical Partnerships with VGI Health Technology to Provide TAEUS for Patient Screening and Biomarker Measurement for Phase 2 Study	21-11-29	CI
VGI Health Technology Hires Darrell Crawford to Scientific Advisory Board	21-09-14	CI
Vgi Health Technology Limited Reports Earnings Results for the Full Year Ended June 30, 2021	21-09-07	CI
Moko Social Media Limited Announces Resignations of Non-Executive Directors	16-04-17	CI
Moko Social Media Limited(ASX:MKB) dropped from S&P/ASX Emerging Companies Index	16-03-21	CI
Moko Social Media Limited Reports Unaudited Consolidated Earnings Results for the Half Year Ended 31 December 2015	16-03-01	CI
MOKO Social Media Announces Management Changes	16-02-18	CI
True Blue Media, LLC, acquired Blue Nation Review from Moko Social Media Limited.	15-11-24	CI
Moko Social Media Limited Announces Retirement of Jeff White as Director	15-11-17	CI
Moko Social Media Limited Announces Consolidated Cash Flow Results for the First Quarter Ended September 30, 2015	15-10-30	CI
Moko Social Media Limited Announces Audited Consolidated Earnings Results for the Year Ended June 30, 2015	15-10-04	CI
Moko Social Media Limited Reports Parent Earnings Results for the Year Ended 30 June 2015	15-09-30	CI
VGI Health Technology Limited Auditor Raises 'Going Concern' Doubt	15-09-29	CI
Moko Social Media Limited Appoints Diana Rhoten as Non-Executive Director with Effect from 1 October 2015	15-09-23	CI
MOKO Social Media Appoints Emma Waldon as Non-Executive Director with Effect from 1 October 2015	15-09-22	CI
Moko Social Media Limited Reports Unaudited Preliminary Consolidated Earnings Results for the Year Ended 30 June 2015	15-08-30	CI
MOKO Social Media Limited completed the acquisition of 10% stake in BigTeams, LLC for $1 million.	15-04-27	CI
Moko Social Media Limited Announces Resignation of Hans de Back, Non Executive Director	15-04-12	CI

Chart VGI Health Technology Limited

Duration

Period

More charts

Company Profile

VGI Health Technology Limited is an Australia-based biotechnology company. The Companyâs MELT3 formulation of Tocotrienols (T3s) is designed to be dissolved in the mouth and then swallowed, which is used for certain non-disease and self-limiting exercise related indications, such as reduction of delayed onset muscle soreness (DOMS), improved muscle recovery after exercise and improved maintenance of muscle power. MELT3 is designed for nutraceuticals and dietary supplements. Its TransT3, a transmucosal delivery platform for T3s, is designed to enhance absorption of the T3s by facilitating sublingual and buccal (transmucosal) absorption. T3s are absorbed into the capillaries below the sublingual and buccal mucosa and then released into the blood stream. Its Tocotrienol ProDrugs (TPD) is a prodrug delivery platform for T3s designed to enhance absorption of T3s into the lymphatic system of the gut and release of T3s into the blood stream.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VGI HEALTH TECHNOLOGY LIMITED	-.--%	1.77M
VERTEX PHARMACEUTICALS INCORPORATED	-3.39%	102B
REGENERON PHARMACEUTICALS, INC.	+2.61%	96.84B
ARGENX SE	-0.82%	21.48B
BIONTECH SE	-18.14%	20.82B
GENMAB A/S	-7.31%	18.6B
WUXI APPTEC CO., LTD.	-40.70%	16.81B
BEIGENE, LTD.	-26.89%	13.78B
NEUROCRINE BIOSCIENCES, INC.	+1.12%	13.4B
SAREPTA THERAPEUTICS, INC.	+22.25%	11.06B

Bio Therapeutic Drugs